• Consensus Rating: Hold
  • Consensus Price Target: $21.40
  • Forecasted Upside: 2.74 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$20.83
▲ +0.01 (0.05%)

This chart shows the closing price for CVET by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Covetrus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CVET and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CVET

Analyst Price Target is $21.40
▲ +2.74% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Covetrus in the last 3 months. The average price target is $21.40, with a high forecast of $27.00 and a low forecast of $16.00. The average price target represents a 2.74% upside from the last price of $20.83.

This chart shows the closing price for CVET for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in Covetrus. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/20/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
5/21/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 1 sell ratings
7/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 1 sell ratings
8/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/13/2022Stifel NicolausDowngradeBuy ➝ Hold$22.00Medium
5/26/2022BarclaysDowngradeOverweight ➝ Equal Weight$26.00 ➝ $21.00Low
5/25/2022William BlairDowngradeOutperform ➝ Market PerformHigh
5/23/2022Morgan StanleyBoost TargetEqual Weight$19.00 ➝ $21.00Low
5/23/2022Raymond JamesDowngradeOutperform ➝ Market PerformLow
5/20/2022Stifel NicolausReiterated RatingBuyLow
5/19/2022The Goldman Sachs GroupLower TargetSell$18.00 ➝ $16.00Low
5/9/2022BarclaysLower Target$38.00 ➝ $26.00High
11/18/2021Morgan StanleyInitiated CoverageEqual Weight$19.00High
11/5/2021Raymond JamesLower TargetOutperform$37.00 ➝ $27.00High
8/9/2021BarclaysLower TargetOverweight$46.00 ➝ $38.00Medium
8/6/2021Raymond JamesLower TargetOutperform$38.00 ➝ $37.00Medium
8/5/2021Credit Suisse GroupInitiated CoverageNeutral$29.00High
7/12/2021GuggenheimUpgradeNeutral ➝ Buy$30.00Medium
3/2/2021Raymond JamesBoost TargetOutperform$31.00 ➝ $39.00High
2/17/2021BarclaysInitiated CoverageOverweight$48.00Low
11/11/2020Credit Suisse GroupBoost TargetNeutral$17.00 ➝ $20.00Medium
10/21/2020Raymond JamesBoost TargetOutperform$26.00 ➝ $31.00High
9/16/2020Stifel NicolausUpgradeHold ➝ Buy$23.00 ➝ $26.00High
9/10/2020Raymond JamesReiterated RatingBuyMedium
8/12/2020Credit Suisse GroupBoost TargetNeutral$12.00 ➝ $14.00High
8/12/2020Stifel NicolausBoost TargetHold$20.00 ➝ $23.00High
8/12/2020Raymond JamesBoost TargetOutperform$14.00 ➝ $26.00High
7/30/2020Stifel NicolausBoost TargetHold$11.00 ➝ $20.00High
5/22/2020Credit Suisse GroupBoost TargetNeutral$10.00 ➝ $12.00Low
4/23/2020Credit Suisse GroupLower TargetNeutral$13.00 ➝ $10.00High
3/4/2020Credit Suisse GroupBoost TargetNeutral$11.00 ➝ $13.00High
10/17/2019Credit Suisse GroupLower TargetNeutral$15.00 ➝ $11.00High
9/9/2019The Goldman Sachs GroupInitiated CoverageSell$11.00High
8/16/2019Credit Suisse GroupSet TargetHold$15.00Low
8/15/2019Raymond JamesLower TargetOutperform$45.00 ➝ $21.00High
8/14/2019Stifel NicolausLower TargetHold$30.00 ➝ $18.00High
5/23/2019GuggenheimInitiated CoverageNeutralHigh
5/22/2019Stifel NicolausInitiated CoverageHold ➝ Hold$30.00High
4/4/2019Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$35.00Low
3/20/2019SVB LeerinkReiterated RatingOutperformHigh
2/27/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$45.00High
2/12/2019William BlairInitiated CoverageOutperform ➝ OutperformN/A
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
1/21/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2022
  • 3 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
5/21/2022
  • 5 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/20/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/20/2022
  • 2 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/19/2022

Current Sentiment

  • 2 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Covetrus logo
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software, data-driven applications, client communications tools, and related services to increase staff efficiency and enhance business health; and solutions that integrate with its software platforms, including client communication services, reminders, data backup services, hardware sales and support, and credit card processing services for veterinary practitioners and animal-health clinics. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as offers shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal, equine, and large-animal markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.
Read More

Today's Range

Now: $20.83
Low: $20.81
High: $20.84

50 Day Range

MA: $20.74
Low: $20.50
High: $20.85

52 Week Range

Now: $20.83
Low: $13.39
High: $23.75

Volume

587,569 shs

Average Volume

894,015 shs

Market Capitalization

$2.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Covetrus?

The following equities research analysts have issued reports on Covetrus in the last year: Barclays PLC, Morgan Stanley, Raymond James, Stifel Nicolaus, The Goldman Sachs Group, Inc., TheStreet, and William Blair.
View the latest analyst ratings for CVET.

What is the current price target for Covetrus?

5 Wall Street analysts have set twelve-month price targets for Covetrus in the last year. Their average twelve-month price target is $21.40, suggesting a possible upside of 2.7%. Raymond James has the highest price target set, predicting CVET will reach $27.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $16.00 for Covetrus in the next year.
View the latest price targets for CVET.

What is the current consensus analyst rating for Covetrus?

Covetrus currently has 1 sell rating and 5 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CVET, but not buy more shares or sell existing shares.
View the latest ratings for CVET.

What other companies compete with Covetrus?

Other companies that are similar to Covetrus include Sanmina, Perficient, Viasat, ACI Worldwide and Mercury Systems. Learn More about companies similar to Covetrus.

How do I contact Covetrus' investor relations team?

Covetrus' physical mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company's listed phone number is (888) 280-2221 and its investor relations email address is [email protected] The official website for Covetrus is www.henryscheinvet.com. Learn More about contacing Covetrus investor relations.